

August 26, 2024

**Acurx Pharmaceuticals**

# **ACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment Conference**

**September 9-11, 2024**

STATEN ISLAND, N.Y., Aug. 26, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP), today announced it will be featured as a presenting company at the H.C. Wainwright 26<sup>th</sup> Annual Global Investment Conference. The conference is being held on September 9-11, 2024.

The in-person venue for the event is the Lotte New York Palace Hotel in New York City located at 455 Madison Avenue. Virtual participation will be staged simultaneously with over 550 company presentations scheduled as live feed or available on-demand.

David P. Luci, President & CEO of the Company, will provide an overview of the Company's business during the presentation.

If you are an institutional investor, and would like to listen to the Company's presentation, please click on the following link ([www.hcwevents.com/annualconference](http://www.hcwevents.com/annualconference)) to register for the conference. Over 550 corporate presentations & panels are available during September 9-11, 2024.

Event: H.C. Wainwright 26<sup>th</sup> Annual Global Investment Conference

Date: September 9-11, 2024

Location: Virtual to start on-demand on September 9 at 7:00 A.M. (ET) or in-person location date/time at the Lotte New York Palace Hotel, New York, NY.

## **About Acurx Pharmaceuticals, Inc.**

Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram+ specific bacterial enzyme DNA polymerase III C (pol III C), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including *Clostridioides difficile*, methicillin resistant *Staphylococcus aureus* (MRSA), vancomycin resistant *Enterococcus* (VRE) and drug-resistant *Streptococcus pneumoniae* (DRSP).

To learn more about Acurx Pharmaceuticals and its product pipeline, please visit

[www.acurxpharma.com](http://www.acurxpharma.com).

## **About H.C. Wainwright & Co.**

H.C. Wainwright is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright's team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998.

For more information visit H.C. Wainwright & Co. on the web at [www.hcwco.com](http://www.hcwco.com)

## **Forward-Looking Statements**

Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the FDA or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2023, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward-looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.

## **Investor Contact:**

Acurx Pharmaceuticals, Inc.  
David P. Luci, President & Chief Executive Officer  
Tel: 917-533-1469  
Email: [davidluci@acurxpharma.com](mailto:davidluci@acurxpharma.com)

View original content: <https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-announces-participation-at-the-hc-wainwright-26th-annual-global-investment-conference-302229628.html>

SOURCE Acurx Pharmaceuticals, Inc.